ZHEJIANG XINGUANG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.02 CNY | -1.52% |
|
+4.36% | -33.49% |
| Sales 2022 | 351M 48.35M | Sales 2023 | 270M 37.2M | Capitalization | 2.65B 365M |
|---|---|---|---|---|---|
| Net income 2022 | 109M 14.99M | Net income 2023 | 64M 8.8M | EV / Sales 2022 | 5.03 x |
| Net cash position 2022 | 737M 101M | Net cash position 2023 | 699M 96.15M | EV / Sales 2023 | 7.22 x |
| P/E ratio 2022 |
23
x | P/E ratio 2023 |
41.4
x | Employees | 315 |
| Yield 2022 |
3.19% | Yield 2023 |
2.41% | Free-Float | 41.35% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.52% | ||
| 1 week | +4.36% | ||
| Current month | +1.57% | ||
| 1 month | -10.55% | ||
| 3 months | -15.94% | ||
| 6 months | -34.44% | ||
| Current year | -33.49% |
1 week
10.72
11.30
1 month
10.3711.91
Current year
8.4517.90
1 year
8.4519.88
3 years
8.4527.56
5 years
8.4530.48
10 years
7.6766.50
| Managers | Title | Age | Since |
|---|---|---|---|
Yue Jun Wang
CEO | Chief Executive Officer | 70 | 97-12-31 |
Bin Bin Xing
DFI | Director of Finance/CFO | 49 | 02-12-31 |
Zhu Ping Sun
CHM | Chairman | 61 | 98-11-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yue Jun Wang
CEO | Chief Executive Officer | 70 | 97-12-31 |
Fu Yin Qiu
BRD | Director/Board Member | 62 | 00-12-31 |
Yuan Yang Jiang
BRD | Director/Board Member | 56 | 12-08-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 11.02 | -1.52% | 885 000 |
| 24-07-02 | 11.19 | +0.90% | 1,330,491 |
| 24-07-01 | 11.09 | +2.21% | 1,462,600 |
| 24-06-28 | 10.85 | -0.09% | 964,305 |
| 24-06-27 | 10.86 | -0.91% | 1,042,100 |
End-of-day quote Shenzhen S.E., July 02, 2024
More quotes
Zhejiang Xinguang Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of Chinese patent medicines, chemical medicines and health foods. The Company's main products are Huangqishengmaiyin, Shenjindan Capsules, American Ginseng Oral Liquid and other products. The treatment scope is mainly cardiovascular and cerebrovascular diseases, trauma diseases, and covers respiratory system, digestive system, urinary system, pediatric diseases and improving immunity. The Company operates its businesses mainly in domestic markets, with Zhejiang Province as its major market.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.49% | 246M | |
| +23.84% | 5.56B | |
| -33.64% | 3.55B | |
| -5.20% | 3.01B | |
| -25.56% | 2.64B | |
| -10.76% | 2.3B | |
| +42.02% | 1.95B | |
| +43.15% | 1.52B | |
| -12.72% | 1.45B | |
| +41.90% | 1.38B |
- Stock Market
- Equities
- 300519 Stock
